Integral Diagnostics (IDX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
29 Oct, 2026Opening remarks and agenda
AGM opened at 10:00 a.m. after quorum confirmation; held in person and virtually, with poll voting on all resolutions.
Agenda covered Chair and CEO addresses, formal resolutions, shareholder questions and voting; FY26 financial report was presented for consideration.
First AGM as Managing Director and CEO, after just under three months in the role; outlined initial observations, actions underway, Q1 trading and FY27 outlook.
Financial performance review
FY26 revenue rose 25.6% to AUD 788.7m, operating EBITDA rose 30.3% to AUD 164.8m, and operating EBITDA margin expanded 80 bps to 20.9%.
FY26 operating NPAT increased 50.2% to AUD 47.4m; statutory NPAT was AUD 22.0m; operating diluted EPS rose 23.6% to AUD 0.126. Capitol Health merger synergies exceeded AUD 14m.
Net debt was AUD 298.9m and pre-AASB 16 net debt/EBITDA was 2.3x at 30 June 2026, versus 2.6x a year earlier.
Q1 FY27 revenue grew 3.0%, or 4.4% excluding closed sites and on a constant-currency basis; FY27 revenue growth guidance is 4%-6%.
FY27 operating EBITDA margin guidance is 19.5%-20.5%, with improvement expected in H2; capex guidance is AUD 50m-AUD 60m.
Board and executive committee updates
Jason Martinez became Managing Director and CEO in August 2026; Jenny Martin joined as CFO in October after becoming available earlier than expected.
Craig White retired as CFO after FY26 results; a new General Manager for Victoria, appointed in September 2026, brought more than 25 years of industry experience.
Chair credited succession planning and thorough handovers with supporting leadership continuity; Ian Kadish was acknowledged for eight years of leadership, including scaling the business and completing the Capitol Health merger.
Raelene Murphy resigned as Audit Committee Chair in March after nine years on the board; Laura McBain took over the role.
Toby Hall and Ingrid Player stood for re-election as directors.
Latest events from Integral Diagnostics
- Revenue up 25.6%, EBITDA margin at 20.9%, with strong growth and margin outlook for FY 2027.IDX
H2 2026 - Revenue up 55.6%, EBITDA up 75.6%, margin at 20.6%, and merger synergies exceeded $14m.IDX
H1 2026 - Strong growth, successful merger, new directors, and ambitious sustainability targets.IDX
AGM 2025 - Strong revenue and margin growth, with merger synergies and industry tailwinds driving outlook.IDX
H2 2025 - Revenue and EBITDA rose, merger and digital strategy advanced, and all resolutions passed.IDX
AGM 2024 - Revenue and EBITDA grew, leverage fell, and a major merger is set to drive future synergies.IDX
H2 2024 - Merger forms ANZ's largest listed imaging group with $10m+ synergies and a 33% premium.IDX
M&A Announcement - Merger to form ANZ imaging leader with 155 clinics, $651M revenue, and $10M+ synergies.IDX
M&A Announcement - Revenue up 9.3%, merger integration on track, and $10m synergy target expected.IDX
H1 2025